09:12 AM EDT, 04/09/2025 (MT Newswires) -- Bausch Health's ( BHC ) Canada unit said Wednesday that it has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance for public drug plan coverage in Canada for its acne vulgaris treatment Cabtreo.

The company said the agreement allows Bausch Health Canada to finalize the listing of Cabtreo under individual government drug plans across Canada, including federal, provincial and territorial programs.

No financial terms of the agreement were disclosed.

Cabtreo has been approved by Health Canada as a triple-combination topical acne treatment, the company said.